# Clinical trials using EGFR slope as an endpoint in chronic kidney disease ## Twenty-two clinical trials used estimated glomerular filtration rate (eGFR) slope as an endpoint in chronic kidney disease studies, with 13 trials using it as a primary outcome and methods for slope calculation varying considerably across studies. # Abstract Twenty-two trials—21 randomized controlled trials and 1 prospective observational study—address chronic kidney disease using estimated glomerular filtration rate (eGFR) slope endpoints. Thirteen trials defined a true eGFR slope (annualized or total rate of decline) as their primary outcome, while 4 trials included slope measures as secondary endpoints; the remainder employed composite outcomes, time-to-event analyses, or point estimates. In the primary endpoint studies, one trial specified an expected difference of 0.75 ml/min/1.73m² per year with 80% power over a 52‐week period. Methods for slope calculation varied considerably; some studies used linear mixed effects or repeated measurements models, weighted analysis of covariance, simple linear regression, or linear random slope models, whereas several trials provided no detailed description of the analytic method. Populations ranged from chronic kidney disease stages 2 to 5, including diabetic kidney disease, autosomal dominant polycystic kidney disease, and immunoglobulin A nephropathy, with trial durations from 52 weeks to 120 weeks. ## Methods We analyzed 24 sources from an initial pool of 36, using 10 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. ### Papers identified with Elicit search n = 36 Papers screened using: - Population - CKD Patients - Population - Not AKI Only - Population - Adult Participants - Primary Outcome - eGFR Slope - Outcome Analysis Quality - Study Design Quality - Study Duration - eGFR Measurement Standards - Multiple Time Points - Intervention Type n = 36 ### Papers screened out n = 12 ### Papers included for extraction n = 24 ## Paper search Using your research question “Clinical trials using EGFR slope as an endpoint in chronic kidney disease”, we [searched](https://support.elicit.com/en/articles/553025) across all trials from the [ClinicalTrials.gov](https://www.clinicaltrials.gov/) corpus. We retrieved the 36 trials most relevant to the query. ## Screening We screened in sources based on their abstracts that met these criteria: - **Population - CKD Patients**: Does the study include participants with chronic kidney disease (any stage)? - **Population - Not AKI Only**: Is the study NOT focused exclusively on acute kidney injury without underlying chronic kidney disease? - **Population - Adult Participants**: Is the study NOT conducted exclusively in pediatric populations (under 18 years)? - **Primary Outcome - eGFR Slope**: Does the study report estimated glomerular filtration rate (eGFR) slope as a primary or secondary endpoint? - **Outcome Analysis Quality**: Is eGFR slope formally analyzed with proper statistical methods (not merely mentioned in passing)? - **Study Design Quality**: Is the study design a randomized controlled trial, controlled clinical trial, systematic review, or meta-analysis? - **Study Duration**: Does the study have a follow-up period of at least 12 months? - **eGFR Measurement Standards**: Does the study use standardized eGFR calculation methods (e.g., CKD-EPI, MDRD)? - **Multiple Time Points**: Does the study report multiple eGFR measurements over time (not just single time-point measurements)? - **Intervention Type**: Does the study evaluate therapeutic interventions (pharmacological, dietary, lifestyle, or device-based) with long-term follow-up rather than focusing solely on acute interventions? We considered all screening questions together and made a holistic judgement about whether to screen in each paper. ## Data extraction We asked a large language model to extract each data column below from each paper. - **Study design**: - Extract the specific type of study design from the methods section. Look for key descriptors such as: - Interventional/observational - Prospective/retrospective - Parallel group - Blinding type (open-label, double-blind, single-blind) - Multicenter or single-site - Specific phase of clinical trial (if applicable) - **Target population characteristics**: - Extract detailed population characteristics from the methods/participants section: - Age range or mean age - Gender distribution - Specific chronic kidney disease (CKD) stage - Inclusion/exclusion criteria related to kidney function - Baseline eGFR (with units and range) - Presence of comorbidities (e.g., diabetes) - **Intervention specifics**: - For intervention studies, extract: - Specific drug/treatment name - Dosage - Frequency of administration - Duration of intervention - Any dose modifications during study - Concurrent treatments or care programs - **Comparison/control condition**: - Describe the control group or comparator condition: - Specific details of control treatment - Whether standard care was maintained - Any placebo or alternative intervention used - **Primary outcome measure**: - Extract the primary outcome as explicitly stated in the study: - Precise outcome definition - Measurement method - Units of measurement - Time point of measurement - **Statistical analysis methods**: - Describe key statistical analysis approaches: - Analysis sets used (e.g., intention-to-treat) - Statistical tests employed - Significant p-value threshold - Methods for handling missing data - Multiplicity or hierarchical testing approaches # Results ## Characteristics of Included Studies | Study | Study Design | Population | Intervention | eGFR Slope Definition | |-----------------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------| | NCT05196347 | Multicenter, randomized, open-label, blinded-endpoint, phase 3 randomized controlled trial | Chronic kidney disease stage 4–5, estimated glomerular filtration rate 10–30, age ≥20 years | Dapagliflozin 5–10 mg daily plus integrated chronic kidney disease care vs. care alone | Difference in estimated glomerular filtration rate slope (ml/min/1.73m²/year) from randomization to end of study, linear mixed model | | NCT02160145 | Multicenter, randomized, double-blind, phase 3 randomized controlled trial | Autosomal dominant polycystic kidney disease, late stage 2–early stage 4 chronic kidney disease, age 18–65 years | Tolvaptan vs. placebo | Mean annualized change in estimated glomerular filtration rate (ml/min/1.73m²/year), Chronic Kidney Disease Epidemiology Collaboration formula | | NCT02957864 | Multicenter, open-label, randomized, phase 4 randomized controlled trial | Human immunodeficiency virus, tenofovir disoproxil fumarate-related nephrotoxicity, estimated glomerular filtration rate ≥30 | Switch to tenofovir alafenamide vs. abacavir | Time to first estimated glomerular filtration rate within 75% of baseline (not a slope) | | NCT06217302 | Multicenter, double-blind, phase 3 randomized controlled trial | Type 1 diabetes, diabetic kidney disease, estimated glomerular filtration rate 20–60, age 18–75 years | Sotagliflozin 200 mg daily vs. placebo | Estimated glomerular filtration rate at end of washout, adjusted by baseline (not a slope) | | NCT03789695 | Single-center, open-label, phase 4 randomized controlled trial | Atrial fibrillation, type 2 diabetes, chronic kidney disease, age ≥18 years | Dabigatran vs. warfarin | Difference in annual estimated glomerular filtration rate decline (slopes), Chronic Kidney Disease Epidemiology Collaboration formula | | NCT03832595 | Single-center, pragmatic, cluster randomized controlled trial | High-risk chronic kidney disease, age 18–85 years | Electronic health record-based population health management vs. usual care | ≥40% decline in estimated glomerular filtration rate or end-stage renal disease (composite, not slope) | | NCT06825676 | Multicenter, cluster randomized controlled trial | Chronic kidney disease, estimated glomerular filtration rate 15–59, age ≥18 years | Provider education vs. routine training | ≥25% decline in estimated glomerular filtration rate, end-stage renal disease, or death (composite, not slope) | | NCT07027774 | Multicenter, open-label, phase 4 randomized controlled trial | Chronic kidney disease stage 4, estimated glomerular filtration rate 10–30, age ≥18 years | Henagliflozin 5/10 mg vs. conventional therapy | Estimated glomerular filtration rate total slope change from week 4 to 52 | | NCT07116928 | Multicenter, double-blind, phase 4 randomized controlled trial | Type 2 diabetes, chronic kidney disease, age ≥18 years | Ganagliflozin 50 mg vs. placebo | Average change in estimated glomerular filtration rate slope from baseline to week 120 | | NCT06291376 | Multicenter, double-blind, phase 3 randomized controlled trial | Immunoglobulin A nephropathy, high risk, estimated glomerular filtration rate ≥30 (main), 20–29 (advanced kidney disease) | Ravulizumab vs. placebo | Change in estimated glomerular filtration rate at week 106 (not a slope) | ### Key points from included studies: - **Study design:** - 21 randomized controlled trials and 1 prospective observational study were included. - Of the randomized controlled trials: - 20 were multicenter; 3 were single-center (2 studies were both multicenter and single-center, counted in both categories). - 2 were cluster randomized controlled trials; 1 was pragmatic; 2 were platform/adaptive designs. - 7 were open-label; 2 were single-blind; 7 were double-blind; 5 were quadruple-blind; 1 was blinded-endpoint. - 3 were phase 2; 10 were phase 3; 6 were phase 4; 1 was factorial; 2 were single-group; 1 was international. - No mention found of phase information for 2 randomized controlled trials. - **Estimated glomerular filtration rate slope definition:** - 13 studies used a true estimated glomerular filtration rate slope (annualized, total, or rate of decline) as an outcome. - 5 studies used a composite outcome including estimated glomerular filtration rate decline (such as ≥25% or ≥40% decline, end-stage renal disease, or death). - 1 study used time to event (time to first estimated glomerular filtration rate within 75% of baseline). - 2 studies reported change in estimated glomerular filtration rate at a specific timepoint (not a slope). - 3 studies used other outcomes not based on estimated glomerular filtration rate slope (kidney fibrosis, drug discontinuation, or chronic kidney disease incidence). - No mention found of a true estimated glomerular filtration rate slope outcome in 8 of the studies. ## Effects ### Estimated Glomerular Filtration Rate Slope as Primary Endpoint | Study | Trial Duration | Slope Calculation Method | Expected Effect Size | Statistical Power | |-----------------|----------------|-------------------------------------------------------------------|-------------------------------------------------|----------------------------------| | NCT05196347 | ≥52 weeks | Linear mixed effects model, estimated glomerular filtration rate slope (ml/min/1.73m²/year) | 0.75 ml/min/1.73m²/year difference | 80% (power calculation) | | NCT02160145 | Up to 61 weeks | Chronic Kidney Disease Epidemiology Collaboration, annualized, weighted analysis of covariance| No mention found | No mention found | | NCT03789695 | 24 months | Mixed model of repeated measurements, Chronic Kidney Disease Epidemiology Collaboration | No mention found | No mention found | | NCT06676384 | 24 months | No mention found | No mention found | No mention found | | NCT01194154 | 24 months | Modification of Diet in Renal Disease-4, simple linear regression | No mention found | No mention found | | NCT06058585 | 108 weeks | No mention found | No mention found | No mention found | | NCT05047263 | 32 months | No mention found | No mention found | No mention found | | NCT07116928 | 120 weeks | No mention found | No mention found | No mention found | | NCT07027774 | 52 weeks | No mention found | No mention found | No mention found | | NCT05056727 | 104 weeks | No mention found | No mention found | No mention found | #### Summary of primary endpoint studies: - **Trial duration:** - 1 study had a duration of 1 year or less (52 weeks). - 5 studies had durations greater than 1 year and up to 2 years (ranging from 61 weeks to 24 months or 104 weeks). - 3 studies had durations greater than 2 years (ranging from 108 weeks to 32 months or 120 weeks). - We found mention of trial duration for all studies. - **Slope calculation method:** - 1 study used a linear mixed effects model for estimated glomerular filtration rate slope. - 1 study used Chronic Kidney Disease Epidemiology Collaboration with annualized, weighted analysis of covariance. - 1 study used a mixed model of repeated measurements with Chronic Kidney Disease Epidemiology Collaboration. - 1 study used Modification of Diet in Renal Disease-4 with simple linear regression. - No mention found of the slope calculation method for 6 studies. - **Expected effect size and statistical power:** - 1 study specified an expected effect size (0.75 ml/min/1.73m²/year difference) and statistical power (80%). - No mention found of expected effect size or statistical power for the other 9 studies. ### Estimated Glomerular Filtration Rate Slope as Secondary Endpoint | Study | Trial Duration | Slope Calculation Method | Expected Effect Size | Statistical Power | |-----------------|----------------|--------------------------|----------------------|-------------------| | NCT02160145 | Up to 61 weeks | Linear mixed model (secondary) | No mention found | No mention found | | NCT06291376 | 106 weeks | No mention found | No mention found | No mention found | | NCT00285298 | 1 year | No mention found | No mention found | No mention found | | NCT03253172 | 2 years | No mention found | No mention found | No mention found | #### Summary of secondary endpoint studies: - Trial duration was more than 1 year in 3 studies and exactly 1 year in 1 study; no studies had a duration less than 1 year. - The slope calculation method was specified in 1 study (using a linear mixed model) and no mention found in 3 studies. - No mention found of expected effect size or statistical power in any of the studies. ### Methodological Variations in Slope Calculation | Study | Slope Calculation Method | Analysis Set | Statistical Test | Multiplicity/Hierarchical Testing | |----------------|-----------------------------------------|--------------------------------------|---------------------------------------|-------------------------------------| | NCT05196347 | Linear mixed effects model | Intention-to-treat, per-protocol | Linear mixed model, Cox proportional hazards for secondary | Closed testing, hierarchical | | NCT02160145 | Weighted analysis of covariance, linear mixed model | No mention found | Analysis of covariance, linear mixed model | No mention found | | NCT03789695 | Mixed model of repeated measurements | No mention found | Mixed model | No mention found | | NCT01194154 | Simple linear regression (per patient) | Full analysis set, safety | Wilcoxon (Mann-Whitney) | No mention found | | NCT04881448 | Linear random slope model | Full analysis set | Shift analysis | No mention found | #### Key methodological points: - Slope calculation methods varied: - Linear mixed effects models or mixed models were used in 2 studies. - Weighted analysis of covariance was used in 1 study. - Mixed model of repeated measurements was used in 1 study. - Simple linear regression (per patient) was used in 1 study. - Linear random slope model was used in 1 study. - Statistical tests included: - Linear mixed models (2 studies) - Analysis of covariance (1 study) - Cox proportional hazards (for secondary analysis, 1 study) - Mixed model of repeated measurements (1 study) - Wilcoxon (Mann-Whitney) (1 study) - Shift analysis (1 study) - Multiplicity or hierarchical testing: - Closed testing with hierarchical procedures was described in 1 study. - No mention found of multiplicity or hierarchical testing in the other 4 studies. ## Summary - Use of estimated glomerular filtration rate slope as an endpoint: - Among the included studies, 13 used estimated glomerular filtration rate slope as a primary outcome and 4 as a secondary outcome. - The remaining studies used composite outcomes, time-to-event, or other non-slope outcomes. - Heterogeneity in methodology: - There was substantial variation in how estimated glomerular filtration rate slope was defined, calculated, and reported. - Slope calculation methods and statistical analyses were inconsistently described, with many studies not specifying key details. - Study populations and interventions: - The studies included diverse populations (e.g., chronic kidney disease of various etiologies, diabetic kidney disease, kidney transplant recipients) and a wide range of interventions (pharmacologic, care models, education, diagnostics). - Reporting of effect size and power: - Only one study reported both an expected effect size and statistical power for the estimated glomerular filtration rate slope endpoint. - Most studies did not mention these parameters. - Generalizability: - The diversity of study designs, populations, and analytic approaches limits direct comparability and synthesis of findings across studies. Overall, these studies demonstrate frequent use of estimated glomerular filtration rate slope as a clinical trial endpoint in chronic kidney disease, but highlight the need for more consistent definitions and analytic methods to improve interpretability across trials. ## References [Lead Sponsor: Boehringer Ingelheim, Sponsor: None\ (2023).NCT04881448: A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291074aaad647a4bc47dc0ad5c54/index.html) [Lead Sponsor: Kaohsiung Medical University, Principal Investigator: Chi-Chih Hung\ (2025).NCT05196347: Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/186229107297016a31f6696d88fb3f2d/index.html) [Lead Sponsor: Erasmus Medical Center, Collaborator: Dutch Kidney Foundation, Collaborator: University Medical Center Groningen, Collaborator: Leiden University Medical Center, Collaborator: Amsterdam UMC, and 1 more\ (2024).NCT03253172: Potassium Supplementation in CKD. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/186229107190eb42eeed74ad0e4f7938/index.html) [Lead Sponsor: Irina Ermolaeva, Sponsor Investigator: Irina Ermolaeva\ (2021).NCT03789695: RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291072dc6eb7e49300b70cc5af12/index.html) [Lead Sponsor: The George Institute, Sponsor: None\ (2025).NCT06058585: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/186229107623fdb92acf4c7f47db53c9/index.html) [Lead Sponsor: Bayer, Sponsor: None\ (2025).NCT05047263: A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291074ffc64fd4230084ada29518/index.html) [Lead Sponsor: First Affiliated Hospital of Wannan Medical College, Collaborator: Jiangsu HengRui Medicine Co., Ltd., Sponsor: None\ (2025).NCT07027774: Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease: A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291074029a43b9b42f2fe7b93d42/index.html) [Lead Sponsor: Universiteit Antwerpen, Collaborator: University Hospital, Antwerp, Principal Investigator: Prof Dr. Marc De Broe\ (2023).NCT03831464: Metformin as RenoProtector of Progressive Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/186229107445d0acee690c95e41d5506/index.html) [Lead Sponsor: Boehringer Ingelheim, Sponsor: None\ (2025).NCT06531824: EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin). NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/18622910731b3ad93a3e2f527e2b8fc8/index.html) [Lead Sponsor: AstraZeneca, Sponsor: None\ (2025).NCT05056727: A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291075d50b730dae3511c605cee7/index.html) [Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Sponsor: None\ (2025).NCT07116928: Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/18622910732cf9b08dd01b2e75a80d8e/index.html) [Lead Sponsor: Alexion Pharmaceuticals, Inc., Sponsor: None\ (2025).NCT06291376: Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN). NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/18622910721df88a7b649c3bc126ffe4/index.html) [Lead Sponsor: Hoffmann-La Roche, Sponsor: None\ (2017).NCT01194154: A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA). NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/18622910748f8b473a735f95f40d8bfa/index.html) [Lead Sponsor: Veterans Medical Research Foundation, Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Collaborator: San Diego Veterans Healthcare System, Collaborator: University of California, San Diego, Collaborator: University of California, San Francisco, and 2 more\ (2022).NCT04258397: Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291072b8f16662f5eebc56535138/index.html) [Lead Sponsor: Yonsei University, Sponsor: None\ (2024).NCT06322056: Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291075579940131abb3844c0add8/index.html) [Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc., Sponsor: None\ (2018).NCT02160145: Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/18622910768f25b1676058fe1ecd14dc/index.html) [Lead Sponsor: University of Pittsburgh, Collaborator: Vanderbilt University Medical Center, Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Principal Investigator: Manisha Jhamb\ (2025).NCT03832595: Kidney Coordinated Health Management Partnership. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291075a4449f2f4b6d0953402b95/index.html) [Lead Sponsor: Erasmus Medical Center, Collaborator: Gilead Sciences, Principal Investigator: Bart Rijnders\ (2020).NCT02957864: Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291074bc3d5c5c58972a363d8f2f/index.html) [Lead Sponsor: Alessandro Doria, Collaborator: Canadian Institutes of Health Research (CIHR), Collaborator: The Kidney Foundation of Canada, Collaborator: The Cleveland Clinic, Collaborator: University of Michigan, and 20 more\ (2025).NCT06217302: Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/186229107715b79eb3f3ef2082179290/index.html) [Lead Sponsor: Guangdong Provincial People's Hospital, Collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital, Collaborator: The First Affiliated Hospital of Chongqing Medical University，China, Collaborator: The First Affiliated Hospital of Dalian Medical University, Principal Investigator: Jiyan Chen\ (2025).NCT06825676: Guideline-diRected Management for Chronic Kidney Disease: EValuation of an Education Program in a National Cluster Randomized Controlled Trial. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291073c71f44d599927f903a4cd8/index.html) [Lead Sponsor: Christian Medical College, Vellore, India, Collaborator: Medical Research Council, Collaborator: India Alliance, Principal Investigator: Suceena Alexander\ (2025).NCT06676384: Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/18622910751a074fbe09faab864b29a8/index.html) [Lead Sponsor: VA Office of Research and Development, Collaborator: Iowa City VA Health Care System, Collaborator: VA Pittsburgh Healthcare System, Collaborator: VA Tennessee Valley Health Care System, Collaborator: VA Hines Health Care, and 1 more\ (2025).NCT06013865: Empagliflozin Treatment in Kidney Transplant Recipients. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291072ede4f894f4e4f874cfa1e5/index.html) [Lead Sponsor: Assistance Publique - Hôpitaux de Paris, Sponsor: None\ (2025).NCT03282409: Prediction of Chronic Renal Disease After Acute Kidney Injury in the Intensive Care Unit. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291076090107273938b316bd945c/index.html) [Lead Sponsor: Walter Reed Army Medical Center, Collaborator: National Kidney Foundation, United States, Responsible Party: None\ (2011).NCT00285298: Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients. NIH](/content/review/3161ff71-dcc2-4d8c-9874-ba544c55a540/source/1862291073d4bcbecf5bcb61b4144c49/index.html) Download BIBDownload RISDownload TXT ## Report Status Gather sources 36 sources found Details Screen sources 24 sources included Details Extract data 144 data points extracted Details Generate report Save PDF BIBLaTeX, ZoteroRISZotero, MendeleyTXTAPA BibliographyPDFPDFDOCXMicrosoft Word Chat Got some follow-up questions?